Mineralocorticoid Receptor Antagonist Pattern of Use in Heart Failure with Reduced Ejection Fraction: Findings from BIOSTAT-CHF
João Pedro Ferreira(Inserm), Faı̈ez Zannad(Centre d’Investigation Clinique Innovation Technologique de Nancy), John G.F. Cleland(University of Glasgow), Piotr Ponikowski(Wroclaw Medical University), Jean‐Loup Machu(Inserm), Abhinav Sharma(Government Medical College), Patrick Rossignol(Inserm), Gerasimos Filippatos(National and Kapodistrian University of Athens), Hans L. Hillege(University Medical Center Groningen), Aeilko H. Zwinderman(Amsterdam Neuroscience), Marco Metra(Vita-Salute San Raffaele University), Chim C. Lang(University of Dundee), Dirk J. van Veldhuisen(University Medical Center Groningen), Adriaan A. Voors(University Medical Center Groningen), Jozine M. ter Maaten(University Medical Center Groningen), Leong L. Ng(University of Leicester), Nilesh J. Samani(University of Leicester), Stefan D. Anker(Bayer (Germany)), Kenneth Dickstein, Nicolas Girerd(Université de Lorraine)
Cited by 102
Related Papers
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2021|13.1k
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
|New England Journal of Medicine|1999|9.1k
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
|European Heart Journal|2012|6.9k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k